Infor M3 for Pharmaceuticals: FDA Compliance & Batch Manufacturing ERP
How Infor M3 supports pharmaceutical and biotech manufacturers with FDA 21 CFR Part 11 compliance, batch management, and quality control.
Infor M3 for Pharmaceutical & Biotech Manufacturing
Pharmaceutical manufacturing operates under some of the strictest regulatory requirements of any industry. ERP systems must support FDA 21 CFR Part 11 compliance, validated batch processing, full traceability, serialization, and rigorous quality management — while also handling the commercial and supply chain complexities of global drug distribution.
Infor M3, available as Infor CloudSuite, provides process manufacturing capabilities that align well with pharmaceutical and biotech requirements. This guide covers what M3 delivers for pharma, where it excels, and how it compares to alternatives.
Evaluating ERP for pharma or biotech? Get independent pricing and partner recommendations.
Pharmaceutical Industry ERP Challenges
Pharma manufacturers face unique ERP requirements that generic systems struggle to address:
| Challenge | Why It's Difficult |
|---|---|
| FDA 21 CFR Part 11 | Electronic records and electronic signatures must be validated, tamper-evident, and auditable |
| Batch traceability | Full genealogy from raw API/excipient lots through production to distributed finished product |
| Validated environments | ERP system must operate within a validated state; changes require change control and revalidation |
| Quality management | GMP (Good Manufacturing Practice) requires integrated deviation management, CAPA, and stability testing |
| Serialization | FDA DSCSA (Drug Supply Chain Security Act) and EU FMD require unique serial numbers on packaging |
| Potency management | Active pharmaceutical ingredient (API) potency varies by batch and affects formulation |
| Shelf life management | Regulatory and commercial shelf life constraints with country-specific requirements |
| Multi-country regulatory | Different approval statuses, labeling requirements, and market authorizations per country |
Infor M3 Capabilities for Pharma
FDA 21 CFR Part 11 Compliance
21 CFR Part 11 governs electronic records and electronic signatures in FDA-regulated environments. Infor M3 provides:
- Electronic signatures — Configurable e-signature capture for critical transactions (batch release, quality approvals, deviation closures)
- Audit trails — Immutable audit logs recording who changed what, when, and why across all regulated transactions
- Access controls — Role-based security with password policies, session management, and user authentication
- Data integrity — System-enforced data validation rules preventing unauthorized modification of batch records
Important: FDA compliance is not a software feature alone — it requires validation. Implementing M3 in a pharma environment includes IQ/OQ/PQ (Installation, Operational, and Performance Qualification) as part of the validation lifecycle. This adds significant time and cost to implementation but is non-negotiable for FDA-regulated facilities.
Batch Process Management
M3's batch manufacturing capabilities support pharmaceutical production workflows:
- Master batch records — Define production recipes with exact ingredient specifications, process parameters, and quality checkpoints
- Batch execution — Real-time recording of actual production data against the master batch record
- Yield tracking — Actual vs. theoretical yield tracking with automatic variance reporting
- Potency-based formulation — Adjust ingredient quantities based on API potency test results for each incoming lot
- Co-product and by-product management — Handle production outputs that generate multiple products from a single process
- Batch genealogy — Full forward and backward traceability linking API lots, excipient lots, intermediate products, and finished goods
Quality Management (GMP)
M3's quality module supports pharmaceutical GMP requirements:
| GMP Requirement | M3 Capability |
|---|---|
| Incoming material testing | Quality inspection at receipt with sampling plans and CoA verification |
| In-process controls | Quality checks linked to production steps with pass/fail disposition |
| Finished goods release | Multi-level quality review and approval workflow before batch release |
| Deviation management | Formal deviation reporting with investigation, root cause analysis, and corrective actions |
| CAPA | Corrective and Preventive Action tracking with effectiveness verification |
| Stability testing | Sample management and stability study tracking for product shelf life determination |
| Supplier qualification | Supplier quality scoring, approved supplier lists, and vendor audit tracking |
| Document control | Version-controlled SOPs and work instructions linked to production processes |
Serialization & Track-and-Trace
The pharmaceutical industry faces increasing serialization mandates:
- FDA DSCSA — Requires unique product identifiers on pharmaceutical packages by November 2024 (extended deadlines apply)
- EU Falsified Medicines Directive (FMD) — Requires serialization and verification for prescription medicines
- China, Brazil, others — Country-specific serialization requirements
M3 provides the product data management foundation for serialization and integrates with specialized serialization solutions (TraceLink, SAP ATTP, Antares Vision) via Infor ION middleware. The integration handles:
- Serial number generation and assignment
- Aggregation (serial to case to pallet)
- Commissioning and decommissioning events
- Regulatory reporting to national verification systems
Shelf Life & Expiry Management
- Lot-level shelf life tracking with configurable date types (manufacturing date, expiry date, retest date)
- FEFO (First Expired, First Out) warehouse management
- Country-specific minimum remaining shelf life requirements
- Automatic quarantine of expired or near-expiry lots
- Stability-based shelf life extension workflows
Implementation Considerations for Pharma
Validation Requirements
Pharma implementations require a validated computing environment per GAMP 5 (Good Automated Manufacturing Practice) guidelines:
| Phase | Activities | Typical Duration |
|---|---|---|
| Planning | Validation strategy, risk assessment, validation master plan | 4–8 weeks |
| IQ (Installation Qualification) | Verify software installed correctly per specifications | 2–4 weeks |
| OQ (Operational Qualification) | Verify system functions per functional specifications | 6–12 weeks |
| PQ (Performance Qualification) | Verify system performs correctly in production-like conditions | 4–8 weeks |
| Ongoing | Change control, periodic review, revalidation as needed | Continuous |
Validation adds 30–50% to the implementation timeline and 20–40% to the cost compared to a non-regulated implementation. This is unavoidable for FDA-regulated manufacturers.
Typical Costs for Pharma Manufacturers
| Company Size | Annual License | Implementation (incl. validation) | First-Year Total |
|---|---|---|---|
| Small Pharma (50–100 users) | $150K–$300K | $300K–$800K | $450K–$1.1M |
| Mid-Market Pharma (100–300 users) | $300K–$700K | $600K–$1.8M | $900K–$2.5M |
| Large Pharma (300+ users) | $700K–$1.5M | $1.5M–$4M+ | $2.2M–$5.5M+ |
Integration Requirements
Pharma facilities typically require integration between M3 and:
- LIMS (Laboratory Information Management System) — Quality test results and CoA data
- MES (Manufacturing Execution System) — Shop floor data collection and batch record execution
- Serialization platforms (TraceLink, SAP ATTP) — Serial number management and regulatory reporting
- DMS (Document Management System) — SOPs, batch records, regulatory submissions
- Regulatory systems — FDA submission tracking, market authorization management
Compare ERP vendors side by side
Use our interactive comparison tool to evaluate features, pricing, and fit across leading ERP systems.
Infor M3 vs SAP for Pharmaceutical Manufacturing
| Dimension | Infor M3 | SAP S/4HANA |
|---|---|---|
| Batch processing | Excellent (native process manufacturing) | Excellent (PP-PI module) |
| 21 CFR Part 11 | Supported (requires validation) | Supported (requires validation) |
| Quality management | Good (integrated QM module) | Excellent (QM module is more mature) |
| Serialization | Via integration (TraceLink, etc.) | Native (SAP ATTP) or via integration |
| Potency management | Good (native) | Good (requires configuration) |
| Global regulatory | Good | Excellent (broader country coverage) |
| Partner ecosystem | Moderate (fewer pharma-specialist partners) | Very large (many pharma-specialist SIs) |
| Implementation cost | $$ | $$$$ |
| Scalability | $50M–$5B revenue | $100M–$100B+ revenue |
| Time to implement | 12–24 months (with validation) | 18–36 months (with validation) |
Key takeaway: SAP S/4HANA offers broader functionality and a larger pharma-specialist partner ecosystem, which is important for very large pharmaceutical companies with complex global operations. Infor M3 provides strong process manufacturing depth at a lower cost point, making it a compelling choice for small-to-mid-market pharma and biotech companies where cost efficiency matters.
For contract manufacturing organizations (CMOs/CDMOs), M3's multi-company architecture and batch process management capabilities are particularly well-suited.
Frequently Asked Questions
Is Infor M3 validated for FDA compliance?
Infor M3 is validatable — meaning the software provides the technical capabilities needed for 21 CFR Part 11 compliance (electronic signatures, audit trails, access controls). However, validation is the customer's responsibility. Each implementation must be validated through IQ/OQ/PQ per GAMP 5 guidelines, and that validation is specific to your configuration and processes.
Can Infor M3 handle pharmaceutical serialization?
M3 does not include a native serialization engine. It integrates with industry-leading serialization platforms (TraceLink, SAP ATTP, Antares Vision) via Infor ION to manage serial number assignment, aggregation, and regulatory reporting. This integration approach is common across ERP vendors — only SAP offers a fully native serialization module.
How does Infor M3 compare to dedicated pharma ERPs like BatchMaster?
BatchMaster offers deeper pharma-specific functionality (formulation, stability testing, regulatory submission management) for smaller organizations, but lacks M3's enterprise scalability and multi-country capabilities. M3 is the better choice for pharma companies with multi-site, multi-country operations or those planning significant growth. BatchMaster is better suited for single-site operations under $50M revenue.
What GAMP 5 software category is Infor M3?
Infor M3 is classified as a Category 4 (configured software) product under GAMP 5. This means it is a commercial-off-the-shelf system that requires configuration to meet specific business requirements. Validation effort focuses on verifying that the configured system meets user requirements (OQ/PQ), not validating the underlying software code.
Next Steps
Evaluating ERP for pharmaceutical manufacturing? Get independent pricing and connect with pharma-experienced implementation partners.
Related pages:
Compare the vendors mentioned in this article
See how Infor CloudSuite, Infor M3 stack up side by side.
Vendors Mentioned in This Article
Related Resources
Infor M3 Pricing & Costs
Compare Infor M3 pricing, licensing, and implementation costs.
ComparisonMicrosoft Dynamics 365 vs Infor M3
Compare Microsoft Dynamics 365 and Infor M3 — features, pricing, and deployment.
ComparisonAcumatica vs Infor M3
Compare Acumatica and Infor M3 — features, pricing, and deployment.
ComparisonEpicor Kinetic vs Infor M3
Compare Epicor Kinetic and Infor M3 — features, pricing, and deployment.
ComparisonInfor CloudSuite vs Infor M3
Compare Infor CloudSuite and Infor M3 — features, pricing, and deployment.
Have questions about this topic?
Our ERP experts can help you find the right solution for your business.